Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antioxidant and renoprotective effects of Imeglimine
jRCT1061230069Recruiting
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of imeglimin in type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoints: Urinary L-FABP and Urinary 8-OHdG. Started Sep 2023; status: recruiting.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1061230069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061230069.